Healthcare stocks are generally higher this morning, including
bio-therapeutics company Pluristem Therapeutics Inc. (
), which is up 3.5% in the pre-market session after reporting
results from the study of its Placental expanded cells.
The developer of placenta-based cell therapies said PLX cells
proved to be "safe" in an animal study assessing maternal and fetal
toxicity. It will pursue the clinical development of PLX-PAD cells
for the indication of pre-eclampsia based on these results, it also
And, Zalicus (
) shares are up 1.5% in pre-market trade as it reports quarterly
loss of $0.46 per share, which is on par with what analysts
expected. But it's revenue of $3.4 million missed the analysts'
mark of $3.8 million, according to Capital IQ estimates.
Finally, shares of Achillion Pharmaceuticals Inc. (
) has jumped near 3% in Monday's premarket session, after the
biopharmaceutical company over the weekend released an encouraging
preclinical profile of ACH-3422, a potential treatment of chronic
hepatitis C viral infection or HCV, with its first-in-human and
proof-of-concept trials expected in the first half of 2014.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.